A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS | NYU Langone Health

Go Back to All Clinical Trials

A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Cervical Cancer
Age: Between 18 years - 100 years
Gender: Female

Other Inclusion Criteria:

1) Cervical cancer that is metastatic, locally advanced, and/or unresectable. 2) Cancer has relapsed after platinum-based therapy. 3) Cancer is measurable on CT scan or similar imaging study.

You may not be eligible for this study if the following are true:

1) Prior immune checkpoint therapy. 2) More than one prior systemic therapy for cancer treatment. 3) Persistent toxicity from prior therapy. 4) Autoimmune disease that has required systemic therapy in the past two years. 5) Significant cardiovascular disease.